ABSTRACTp53 mutations, occurring in two-thirds of all human cancers, confer a gain of function phenotype, including the ability to form metastasis, the determining feature in the prognosis of most human cancer. This effect seems mediated at least partially by its
ability to physically interact with p63, thus affecting a cell invasion pathway, and accordingly, p63 is deregulated in human cancers. In addition, p63, as an ‘epithelial organizer’, directly impinges on epidermal mesenchimal transition, stemness, senescence, cell death and cell cycle arrest, all determinant in cancer, and thus p63 affects chemosensitivity and chemoresistance. This demonstrates an important role for p63 in cancer development and its progression, and the aim of this review is to set this new evidence that links p63 to metastasis within the context of the long conserved other functions of p63.
REFERENCES1. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominantnegative activities. Mol Cell 1998; 2: 305–316.
2. Schmale H, Bambergeric C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 1997; 15: 1363–1366.
3. Trink B, Okami K, Wu L, Spiuranpong V, Jen J, Sidransky D. A new human p53 homolog. Nat Med 1998; 4: 747–748.
4. Senoo M, Seiki N, Ohira M, Sugano S, Watanabe M, Tachibana M et al. A second p53- related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 1998; 248: 603–607.
5. Senoo M, Seiki N, Ohira M, Sugano S, Watanabe M, Tachibana M et al. A second p53- related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 1998; 248: 603–607.
6. Linzer DIH, Levine AJ. Characterization of a 54,000 MW cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43–52.
7. Lane D, Crawford LV. T-antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261–263.
8. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605–615.
9. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 2011; 12: 259–265.
10. Leslie M. Brothers in arms against cancer. Science 2011; 331: 1551–1552.
11. Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of P63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 2011; 16: 296–327.
12. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209–218.
13. Vanbokhoven H, Melino G, Candi E, Declercq W. p63, a story of mice and men. J Invest Dermatol 2011; 131: 1996–1207.
14. Yang A, McKeon F. p63 and p73: p53 mimics, menace and more. Nat Rev Mol Cell Biol 2000; 1: 199–207.
15. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002; 18: 90–95.
16. Gressner O, Schilling T, Lorenz K, Schulze SE, Koch A, Schulze-Bergkamen H et al. TAp63a induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24: 2458–2471.
17. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z et al. p63 protects the female germ line during meiotic arrest. Nature 2006; 444: 624–628.
18. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapyinduced death. Nat Med 2009; 15: 1179–1185.
19. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714–718.
20. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708–713.
21. Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, Thesleff I. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 2006; 133: 1553–1563.
22. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A et al. Differential roles of p63 isoforms in epidermal devlopment: selective genetic complementation in p63 null mice. Cell Death Differ 2006; 13: 1037–1047.
23. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev 2006; 20: 3185–3197.
24. Turi A, Liuni S, Pesole G, De Grassi A, Caratozzolo MF, D’Erchia AM et al. p53FamTaG: a database resource of human p53, p63 and p73 direct target genes combining in silico prediction and microarray data. BMC Bioinform 2007; 8 (Suppl 1): S20.
25. Vigano MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C et al. New p63 targets in keratinocytes identified by a genome-wide approach. EMBOJ 2006; 25: 5105–5116.
26. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 2006; 24: 593–602.
27. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986–990.
28. Beaudry VG, Attardi LD. SKP-ing TAp63: stem cell depletion, senescence, and premature aging. Cell Stem Cell 2009; 5: 1–2.
29. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene.Nucleic Acids Res 2009; 37: 6092–6104.
30. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99: 143–153.
31. Joerger AC, Rajagopalan S, Natan E, Veprintsev DB, Robinson CV, Fersht AR. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci USA 2009; 106: 17705–17710.
32. Coutandin D, Lo¨hr F, Niesen FH, Ikeya T, Weber TA, Scha¨ fer B et al. Conformational stability and activity of p73 require a second helix in the tetramerization domain. Cell Death Differ 2009; 16: 1582–1589.
33. Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Scha¨ fer B, Hannewald J et al. DNA damage in oocytes induces a switch of the quality control factor TAp63a from dimer to tetramer. Cell 2011; 144: 566–576.
34. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 2006; 103: 12753–12758.
35. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008; 14: 10–21.
36. Mills AA, Qi Y, Bradley A. Conditional inactivation of p63 by Cre-mediated excision. Genesis 2002; 32: 138–141.
37. Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin Y-L et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 2009; 5: 64–75.
38. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 2005; 19: 1986–1999.
39. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363–373.
40. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M et al. p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci USA 2007; 104: 3255–3260.
41. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004; 18: 126–131.
42. Romano RA, Ortt K, Birkaya B, Smalley K, Sinha S. An active role of the DN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One 2009; 4: e5623.
43. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60: 4016–4020.
44. Lo Iacono N, Mantero S, Chiarelli A, Garcia E, Mills AA, Morasso MI et al. Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects. Development 2008; 135: 1377–1388.
45. Wolff S, Talos F, Palacios G, Beyer U, Dobbelstein M, Moll UM. The alpha/beta carboxyterminal domains of p63 are required for skin and limb development. New insights from the Brdm2 mouse which is not a complete p63 knockout but expresses p63 gamma-like proteins. Cell Death Differ 2009; 16: 1108–1117.
46. Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell 2002; 2: 607–616.
47. Dohn M, Zhang S, Chen X. p63alpha and deltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001; 20: 3193–3205.
48. Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000; 19: 3126–3130.
49. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560–564.
50. Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007; 129: 523–536.
51. Mills AA. p63: oncogene or tumor suppressor? Curr Opin Genet Dev 2006; 16: 38–44.
52. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371–386.
53. Westfall MD, Pietenpol JA. p63: molecular complexity in development and cancer. Carcinogenesis 2004; 25: 857–864.
54. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M et al. TAp63 and DNp63 in cancer and epidermal development. Cell Cycle 2007; 6: 274–285.
55. Di Como CJ, Urist MJ, Babayan I, Drobniak M, Hedvat CV, Teruya-Feldstein J et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8: 494–501.
56. Das RK, Pal M, Barui A, Paul RR, Chakraborty C, Ray AK et al. Assessment of malignant potential of oral submucous fibrosis through evaluation of p63, E-cadherin and CD105 expression. J Clin Pathol 2010; 63: 894–899.
57. Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int 2009; 104: 915–918.
58. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A et al. Cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009; 18: 595–600.
59. Kellogg Parsons J, Saria EA, Nakayama M, Vessella RL, Sawyers CL et al. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate 2009; 69: 559–569.
60. Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E et al. Loss of DNp63a promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res 2009; 69: 9263–9270.
61. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161: 1199–1206.
62. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 2006; 66: 7589–7597.
63. Karni-Schmidt O, Castillo-Martin M, HuaiShen T, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011; 178: 1350–1360.
64. Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol 2011; 15: 108–116.
65. Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, Yamada A et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 2009; 100: 2054–2059.
66. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15–25.
67. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34: 1805–1811.
68. Uramoto H, Yamada S, Hanaquiri T. Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res 2010; 30: 4717–4720.
69. Righi L, Graziano P, Fornari A, Rossi G, Barbareschi M, Cavazza A et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011; e-pub ahead of print 18 January 2011. doi: 10.1002/cncr.25830.
70. Iacono ML, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M et al. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol 2011; 6: 473–481.
71. Quade BJ, Yang A, Wang Y, Sun D, Park J-J, Sheets EE et al. Expression of the p53 homologue p63 in early cervical neoplasia. Gynecologic Oncol 2001; 80: 24–29.
72. Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001; 32: 479–486.
73. Hanker L, Karn T, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M et al. Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Res Treat 2010; 122: 765–775.
74. Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S et al. The integrin alpha(v)beta(3–5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer
Res 2011; 71: 937–945.
75. Aikawa E, Kawahara A, Kondo K, Hattori S, Kage M. Morphometric analysis and p63 improve the identification of myoepithelial cells in breast lesion cytology. Diagn Cytopathol 2011; 39: 172–176.
76. Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. Mod Pathol 2011; 24: 502–511.
77. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417–427.
78. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004; 114: 2063–2072.
79. Zangen R, Ratovitski E, Sidransky D. DNp63a levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4: 1313–1315.
80. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63: 7113–7121.
81. Crum CP, McKeon F. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol Mech Dis 2010; 5: 349–371.
82. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumorspecific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 2006; 66: 9362–9368.
83. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97: 5462–5467.
84. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45–56.
85. Pruneri G, Fabris S, Dell’Orto P, Biasi MO, Valentini S, Del Curto B et al. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005; 206: 337–345.
86. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 2005; 19: 1986–1999.
87. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, Petherbridge KM et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 2006; 103: 8435–8440.
88. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9: 5501–5507.
89. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327–1341.
90. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87–98.
91. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S et al. A microRNA targeting dicer for metastasis control. Cell 2010; 141: 1195–1207.
92. Sigal A, Rotter V. Oncogenic mutations of the p53 suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788–6793.
93. Lang GA, Iwakuma T, Suh YA, Liu G, Rao A, Parant JM et al. Gain-of-function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861–872.
94. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain-offunction in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847–860.
95. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285–295.
96. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.
97. Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T, Mu¨ ller M. Dominant negative (deltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun 2010; 396: 335–341.
98. Lu C, Lu S, Liang W, Li J, Dou X, Bian C et al. TAp63a mediates chemotherapeutic agent-induced apoptosis in human bone marrow mesenchymal stem cells. Stem Cells Dev 2011; e-pub ahead of print 24 February 2011; doi:10.1089/scd.2010.0329; PMID: 21142794.
99. Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 2009; 28: 2348–2357.
100. Fomenkov A, Zangen R, Huang YP, Osada M, Guo Z, Fomenkov T et al. RACK1 and stratifin target deltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 2004; 3: 1285–1295.
101. Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO et al. DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res 2011; 71: 1167–1176.
102. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B et al. Phospho-DNp63a is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 2011; 18: 1220–1230.
103. Yuan M, Luong P, Hudson C, Gudmundsdottir K, Basu S. c-Abl phosphorylation of DNp63a is critical for cell viability. Cell Death Dis 2010; 1: e16.
104. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806–809.
105. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8: 551–561.
106. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009; 11: 1451–1457.
107. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1: 369–379.
108. Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/ Notch cascade. J Clin Invest 2010; 120: 103–114.
109. Medawar A, Virolle T, Rostagno P, de la Forest-Divonne S, Gambaro K, Rouleau M et al. DeltaNp63 is essential for epidermal commitment of embryonic stem cells. PLoS One 2008; 3: e3441.
110. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E et al. DNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 2011; 18: 887–896.
111. Chiang CT, Chu WK, Chow SE, Chen JK. Overexpression of DNp63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol 2009; 219: 117–122.
112. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The DNp63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003; 23: 2264–2276.
113. Petitjean A, Ruptier C, Tribollet V, Hautefeuille A, Chardon F, Cavard C et al. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with deltaNp73. Carcinogenesis 2008; 29: 273–281.
114. Candi E, Rufini A, Terrinoni A, Giamboi-Miraglia A, Lena AM, Mantovani R et al. DNp63 regulates thymic development through expression of FgfR2 and Jag2. Proc Natl Acad Sci USA 2007; 104: 11999–12004.
115. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol 2009; 10: 207–217.
116. Cordani N, Pozzi S, Martynova E, Fanoni D, Borrelli S, Alotto D et al. Mutant p53 subverts p63 control over KLF4 expression in keratinocytes. Oncogene 2011; 30: 922–932.
117. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H et al. DNp63a is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011; 8: 164–176.
118. Sommer M, Poliak N, Upadhyay S, Ratovitski E, Nelkin BD, Donehower LA et al. DNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle 2006; 5: 2005–2011.
119. Higashikawa K, Yoneda S, Tobiume K, Taki M, Shigeishi H, Kamata N. Snail-induced down-regulation of deltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res 2007; 67: 9207–9213.
120. Higashikawa K, Yoneda S, Tobiume K, Saitoh M, Taki M, Mitani Y et al. DeltaNp63alphadependent expression of Id-3 distinctively suppresses the invasiveness of human squamous cell carcinoma. Int J Cancer 2009; 124: 2837–2844.
121. Cates JM, Dupont WD, Barnes JW, Edmunds HS, Fasig JH, Olson SJ et al. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol 2008; 16: 251–262.
122. Lindsay J, McDade SS, Pickard A, McCloskey KD, McCance DJ. Role of deltaNp63gamma in epithelial to mesenchymal transition. J Biol Chem 2011; 286: 3915–3924.
123. Caserta TM, Kommagani R, Yuan ZA, Robbins DJ, Merce CA, Kadakia MP. p63 overexpression induces the expression of sonic hedgehog. Mol Cancer Res 2006; 4: 759–768.
124. Li N, Singh S, Cherukuri P, Li H, Yuan Z, Ellisen LW et al. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. Stem Cells 2008; 26: 1253–264.
125. Belyi VA, Levine AJ. One billion years of p53/p63/p73 evolution. Proc Natl Acad Sci USA 2009; 106: 17609–17610.
126. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–4751.